Abstract
The pharmacology of cefotaxime and the metabolite desacetyl cefotaxime was studied in 40 patients with various degrees of renal and hepatic failure who received 0.5 or 1 g of cefotaxime intravenously. Patients with severe renal impairment (creatinine clearance, 3 to 10 ml/min) had a cefotaxime serum half-life of 2.6 h and desacetyl cefotaxime serum half-life of 10.0 h. The equivalent figures were 1.0 and 1.5 h, respectively, in subjects with normal renal function. The presence of an acute coexisting illness together with severe renal impairment was associated with a further prolongation of the serum half-lives. Hepatic dysfunction was accompanied by a reduction in desacetyl metabolite formation. A reduction of cefotaxime dosing to 0.5 g twice a day would appear prudent when the creatinine clearance is 5 ml/min or less to avoid accumulation of the parent compound and the metabolite.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Fu K. P., Neu H. C. beta-lactamase stability of HR 756, a novel cephalosporin, compared to that of cefuroxime and cefoxitin. Antimicrob Agents Chemother. 1978 Sep;14(3):322–326. doi: 10.1128/aac.14.3.322. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Korhonen U. R., Jounela A. J., Pakarinen A. J., Pentikäinen P. J., Takkunen J. T. Pharmacokinetics of digoxin in patients with acute myocardial infarction. Am J Cardiol. 1979 Nov;44(6):1190–1194. doi: 10.1016/0002-9149(79)90187-5. [DOI] [PubMed] [Google Scholar]
- Wise R., Rollason T., Logan M., Andrews J. M., Bedford K. A. HR 756, a highly active cephalosporin: comparison with cefazolin and carbenicillin. Antimicrob Agents Chemother. 1978 Dec;14(6):807–811. doi: 10.1128/aac.14.6.807. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wise R., Wills P. J., Andrews J. M., Bedford K. A. Activity of the cefotaxime (HR756) desacetyl metabolite compared with those of cefotaxime and other cephalosporins. Antimicrob Agents Chemother. 1980 Jan;17(1):84–86. doi: 10.1128/aac.17.1.84. [DOI] [PMC free article] [PubMed] [Google Scholar]